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COLORECTAL CANCER PATIENTS IN THE VETERAN POPULATION: A HEALTH
CARE COST AND UTILIZATION ANALYSIS IN THE UNITED STATES
Wang L1, Li L1, Huang A1, Baser O2
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan,
Ann Arbor, MI, USA
OBJECTIVES:To assess the clinical and economic burden of colorectal cancer in the
US veteran population.METHODS: A retrospective study (October 01, 2005 to Sep-
tember 30, 2010) was conducted using the Veterans Health Affairs Medical SAS
Datasets. Patients diagnosed with colorectal cancer were included in the study.
Health care resource utilization and costswere assessed in the 12-month follow-up
period. Patients’ demographic, clinical and discharge statuses were compared us-
ing Chi-square testing and standardized differences. Student t-tests were used for
the means of continuous variables. Mortality and survival rates were calculated
using the Kaplan and Meier method and the PROC LIFETEST procedure. RESULTS:
In patients diagnosed with colorectal cancer (n92,494) in the total mortality rates
in the 12-month follow-up period were 33.11% (n28,716), with 52.72% for patients
age 39 and under, 25.53% for patients age 40 to 64, and 35.81% for patients age 65
and above. The most commonly ordered laboratory tests were sodium (4.12%),
potassium (4.07%), glucose quant (3.97%), chloride (3.93%) and creatinine (3.87%).
The average number of inpatient visits (0.58), emergency room (ER) (0.37), physician
office (28.55) and outpatient visits (28.89) were calculated for colorectal cancer
patients per patient, separately. We also calculated the percentage of inpatient
(29.33%), ER (17.86%), physician office (99.74%) and outpatient visits (99.78%). Pa-
tient expenditures for inpatient visits ($12,032), ER ($139), physician office ($8,728)
and outpatient visits ($9,005) were also computed. CONCLUSIONS: Based on cur-
rently available data, this analysis suggests that despite a standard mortality rate
increase with patient age, the highest mortality rate for colorectal cancer patients
in this population occurs among patients under age 40.
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ANALYSIS OF USING TRASTUZUMAB FOR THE TREATMENT OF ADVANCED
GASTRIC CANCER WITH HER2 POSITIVE
Lechuga D1, Gay JG2, Alva M1, Sanchez-kobayashi R2
1Roche Mexico, Mexico City, Mexico, 2TI Salud, Mexico City, Mexico
OBJECTIVES: To analyze which alternative treatment for advanced gastric cancer
with HER2 positive gives a better outcome in terms of life years gained (LY gained).
METHODS:An analysis of effectiveness using as outcomemeasure overall survival
by a Markov model with 3 stages: progression-free, progression and death, as al-
ternatives to taking trastuzumab plus chemotherapy (capecitabine/fluorouracil
and cisplatin), epirubicin  cisplatin  fluorouracil (ECF), cisplatin 
capecitabine  epirubicine (ECX), epirubicin  oxaliplatin  fluorouracil (EOF) and
epirubicin  oxaliplatin  capecitabine (EOX). The outcome was LY gained. The
effectiveness was obtained through survival curves of Kaplan-Meier overall sur-
vival for patients with advanced gastric cancer and overexpression of HER2 ob-
tained from ToGA (Bang et al 2010). The time horizon considered in the model was
8 years (96 months). This time horizon was also in the TA 208 evaluation appraisal
of trastuzumab as first-line treatment of the NICE. RESULTS: The treatment of
trastuzumab  chemotherapy proved more effectiveness than all other treatment
options. Trastuzumab generates 1.33 LY gained (life years) versus 1.04 of the che-
motherapies with capecitabine (ECX and EOX) and 0.92 of the chemotherapies with
fluorouracil (ECF and EOF) in HER2 positive patients. CONCLUSIONS: Trastuzumab
treatment for HER2 positive advanced gastric cancer proved to be the alternative
with more LY gained in comparison to all treatment options considered in this
study.
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IMPACT OF ANTICHOLINERGIC LOAD OF MEDICATIONS ON THE LENGTH OF
STAY OF CANCER PATIENTS IN HOSPICE CARE
Gupte KP, Wu WK
St. John’s University, Jamaica, NY, USA
OBJECTIVES: Anticholinergic medications are effective in the symptom control of
advanced cancer patients. However, use of these medications has been associated
with increased risk of side effects, which might lead to premature mortality. Ac-
cordingly, the study was conducted to examine the effect of increasing anticholin-
ergic load on the length of stay (LOS) of cancer patients in hospice care.METHODS:
2007 NHHCS was used as the data source. Cox Proportional Hazards Model was
used to investigate the risk of death among users of moderate and high anticho-
linergic load compared with users of low anticholinergic load in presence of other
prognostic factors. Patients whowere discharged alive andwhose discharge status
was unknown were censored. Data Analysis was performed using SAS version 9.1.
RESULTS: Of the 4109 patients receiving hospice care in 2007, 43.8% patients suf-
fered from a cancer diagnosis. Cancer patients (n  1801) on moderate anticholin-
ergic load had 12.7% lower hazard of death (p  0.0244) while those on high anti-
cholinergic load had 15.6% lower hazard of death (p 0.0071) as compared to those
patients on low anticholinergic load. Among other prognostic factors, non-elderly
age group (HR 1.33; p  0.0001), male gender (HR 1.17; p  0.0019), white race (HR
1.44; p  0.0005), metropolitan agency (HR 1.17; p  0.0039), non-profit agency (HR
1.23; p  0.0029), severe ADL dependency (HR 1.63; p  0.0001) and cognitive im-
pairment (HR 1.12; p  0.0358) were significantly associated with higher hazard of
death. CONCLUSIONS: The results suggest that increasing anticholinergic load
does not harm cancer patients using hospice care. The protective effect of increas-
ing anticholinergic load on the LOSmight be due to their clinical appropriateness in
the palliation of symptoms in advanced cancer patients. Future studies need to
evaluate the effect of increasing anticholinergic load on the quality-of-life of ad-
vanced cancer patients.
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INCIDENCE OF METASTATIC HORMONE RECEPTOR POSITIVE (HR) BREAST
CANCER IN THE UNITED KINGDOM (UK): DATA NEEDED!
Fordyce TA1, Mowat FS1, Fryzek J2, Lau EL1
1Exponent, Inc., Menlo Park, CA, USA, 2Exponent, Inc., Alexandria, VA, USA
OBJECTIVES: In 2008, breast cancer accounted for 16% of cancer deaths in British
women. Although early stage breast cancer is treatable, prognosis for metastatic
breast cancer (mBC) cancer patients is poor. Information on incidence of HRmBC
in the UK is not readily available, as data on stage was not collected by cancer
registries until 2008. In this study,we estimate the incidence of HRmBC in theUK.
METHODS: Data reported by the International Agency for Research on Cancer was
used to estimate breast cancer incidence for 2008. Values were cross-checked with
Cancer Research UK.We then estimated the number of patients that were likely to
be HR and the number that were likely to progress to metastatic disease using
data from published literature and from the National Institute for Health and Clin-
ical Excellence. Surveillance, Epidemiology, and End Results data were used to
further cross-check values. RESULTS: It is estimated that of 46,458 incident breast
cancer patients per annum in the UK (89 per 100,000), 34,834 are HR (75%). Based
on 17 regional registries in the US, 1761 women were reported to be HR with
metastatic disease (63.5% of mBC cases) in 2008. Most literature-based values esti-
mate that up to 50% of breast cancer patients progress tometastatic disease. Based
on this assumption, among UK HR cases, an estimated 17,421 will likely progress
to metastatic disease (50% of HR cases or 37.5% of incident breast cancer cases).
CONCLUSIONS: There is a large gap in the literature on the incidence and preva-
lence rates of HR mBC in the UK. Our estimates revealed that most newly diag-
nosed breast cancer in the UK is HR, and about half will progress to metastatic
disease. The large number of HRmBC patients in the UK represents a significant
clinical and health care burden.
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EPIDEMIOLOGY OF THE NON-HODGKIN LYMPHOMA COLOMBIA 2000-2011
Romero martin RM1, Chávez Diana CD2
1Fundación Salutia, Centro de investigaciones en economía, gestión tecnología en salud, Bogotá
D.C., Colombia, 2Fundación Salutia, Centro de investigaciones en economía, gestión tecnología en
salud, Bogotá D.C., Distrito Capital, Colombia
OBJECTIVES: Review the Non-Hodgkin lymphoma (NHL) in the last 10 years and its
epidemiological behavior in Colombia.METHODS:We conducted a systematic re-
view of the literature on behavior and treatment of NHL (2000-2011), in PubMed,
EBSCO, Science Direct and Cochrane; employing combined MeSH terms with the
mean descriptor Non-Hodgkin Lymphoma. To determine the epidemiological be-
havior of the disease reviewed the Cancer Registry of Cali, deaths according to vital
statistics of DANE (ICD-10, C82-C85), GLOBOCAN records and Mortality Atlas Can-
cer in Colombia 2002-2006. RESULTS: In the period 2001-2005, the estimated inci-
dence rate for NHL was 10.5 in men and 7.8 women per 100,000 per-year. The
incidence rate is multiplied almost 10 times between 45 and 49 years old, until 25
times between 65 and 69 years and 30 times after 80 years of age. In 2000-2008, the
mortality rate was 1.87 per 100,000, it was: 2.11 in men and 1.63 in women per
100,000, for amale: female ratio of 1.26. Themedian age of the disease to Colombia
is 56 years. In 2006, the NHL was ranked eleventh in mortality in our country.
Among males was the tenth leading cause of death, and in women, the twelfth.
CONCLUSIONS: The NHL mortality rate in the period 2000-2008 shows a slight
upward trend, especially in the years 2005 and 2008. In Colombia, the increased risk
of death inmen compared to women, the distribution of deaths by age group, with
peaks in young adults (15-44 years) and seniors (65 years) - and the geographical
distribution has the highest mortality in the central region (area of industrial ac-
tivity) promote occupational scenarios. The treatment of NHL has advanced signif-
icantly in the last decade, with high mortality neoplasia became a curable type of
cancer in a high proportion of patients.
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EFFECT OF TREATMENTS FOR LATE-STAGE PROSTATE CANCER ON SURVIVAL
Ali AA, Xiao H, Adunlin GB
Florida A&M University, Tallahassee, FL, USA
OBJECTIVES:This study examined the relative effectiveness of treatments increas-
ing the survival time for late-stage prostate cancer. METHODS: Cox proportional
hazard regression model was used to assess overall survival in relation to various
treatments adjusting for confounding factors. Survival time was calculated from
the date of initial diagnosis to the last day of contact. Patient demographics, type of
health insurance stage, and grade of the tumor were extracted from Florida Cancer
Data System. Socioeconomic factorswere extracted fromCensus 2000. The types of
co-morbidity were formulated following the Elixhauser Index. The Census 2000
and Florida Agency for Health Care and Administration datasets were linked with
the Florida Cancer Data system for the time betweenOctober 1, 2001 andDecember
31, 2007 with survival being measured through October 31, 2008. RESULTS: A total
of 4336 men who had late-stage prostate cancer in Florida were analyzed. The
average age at the time of diagnosis was 65 and the average survival time was 253
days. Among patients who had late-stage prostate cancer, 59 percent received
surgical treatment only. The log-rank andWilcoxon tests indicated that therewere
significant differences in survival time by treatment options. The cox proportional
hazard regression result showed that patients who had received radiation only,
hormone only, and those who had chosen active surveillance were at a higher risk
of having shorter survival time than those who had received surgery only. The
existence of one or more co-morbidity, being diagnosed at an older age, and being
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uninsuredwere associatedwith highermortality. CONCLUSIONS: The study found
that men who received the following treatments received radiation only, hormone
only, chose active surveillance, with co-morbidity and of advanced age had lower
survival benefit. Further, research that is foucsed on the specific cause of death
may help understand the impacts of treatment and covariates on prostate cancer
survival.
CANCER – Cost Studies
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A BUDGET IMPACT ANALYSIS OF VINORELBINE INTRODUCTION ON CROATIAN
POSITIVE DRUGS LIST IN BREAST CANCER TREATMENT
Vitezic D1, Hadzic-Kostrencic C2, Petkovic M1, Mrsic Pelcic J3
1University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, 2Pliva
Croatia Ltd., Zagreb, Croatia, 3University of Rijeka, Rijeka, Croatia
OBJECTIVES:Vinorelbinewas not available in breast carcinoma treatment through
theCroatianNational Health Insurance (CNHI) PositiveDrugs List (PDL) and the aim
of our studywas to analyse the possible financial impact of vinorelbine inclusion to
the CNHI PDL. METHODS: A specific clinical guideline for vinorelbine reimburse-
ment through the CNHI PDL is proposed according to evidence-based medical cri-
teria and themain international guidelines. We have developed the budget impact
analysis (BIA) model and calculated the number of patients who will be treated
with vinorelbine in three-years’ period after the reimbursement following the pro-
posed clinical guideline. The share of vinorelbine has been estimated usingmarket
data and the price of vinorelbine has been calculated according to the Croatian
MoH Pricing Ordinance. The total costs for CNHI has been calculated using a refer-
ent scenario (without vinorelbine) and a scenario with vinorelbine reimbursement.
Monte Carlo simulation has been performed too. RESULTS: The total number of
patients who could be potential candidates for the vinorelbine treatment will be
200-300 per year. An average annual drug cost per patient is estimated at 628.50
USD. Monte Carlo simulation results in breast cancer treatment showed the cost of
1,010,000 USD per year in scenario without vinorelbine and declining costs in sce-
nario with vinorelbine from 879,299 USD in the first year of treatment to 614,411 in
the third year. The savings of vinorelbine introduction during the three-year period
will be 791,286 USD. CONCLUSIONS: The inclusion of vinorelbine to PDL, according
to the reimbursement criteria, demonstrates a net reduction of budget expendi-
tures for CNHI (savings) in the period of three years due to the effects of substitu-
tion of other cytostatic drugs with vinorelbine (only in the indication of breast
cancer). Our study supports the usage of vinorelbine from the clinical and phar-
macoeconomical aspect and it could give certain clinical benefits for these pa-
tients.
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CLINICAL BENEFIT AND ECONOMIC IMPACT OF THREE-YEARS OF ADJUVANT
IMATINIB IN KIT GASTROINTESTINAL STROMAL TUMORS (GIST)
Sanon M1, Parthan A1, Taylor DC1, Coombs J2, Paolantonio M2, Sasane M2
1OptumInsight, Medford, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA
OBJECTIVES: Treatment with 3 years (yrs) versus 1 yr of adjuvant imatinib (IM)
therapy for patients with surgically resected kit GIST with a high risk of recur-
rence has been shown to significantly improve recurrence-free survival (RFS) &
overall survival (OS).Therefore the budgetary impact of treating patients with GIST
with 3yrs vs. 1 yr of IM over a 3-year horizon was assessed. METHODS: A Markov
model was developed to predict GIST recurrence and treatment costs. Patients
enter the model after surgery and transition among three health states: free of
recurrence, recurrence, & death. Monthly recurrence & mortality rates were de-
rived from SSGXVIII/AIO clinical trial & published literature. Number of eligible
patients was estimated from Survival Epidemiology and End Results. Costs and
discontinuation rates were estimated from trial and published sources. The bud-
getary impact was estimated by comparing health care costs for 3 years versus 1yr
of IM and calculated as total & per member per month (PMPM) cost. Sensitivity
analyses were conducted. RESULTS: Themodel estimated the budgetary impact of
introducing 3 yr imatinib in a hypothetical health plan of 10 millionmembers with
36 surgically resected GIST incident patients. The model predicted that recurrence
or death would be avoided in 9 additional patients. The net budgetary impact per
patient per month would be $1090 in years 2 and $2574 in yearr 3, and cost $0.01
PMPM in years 2 & 3. Treatment with 3 years IM would increase the budget by 15%
in year 2 and 28% in year 3. Model results at yr 3 were sensitive to cost of imatinib
and recurrence rates. CONCLUSIONS: Treatment with 3 years of imatinib has been
shown to significantly improve RFS and OS. The budgetary impact associated with
this survival gain is predicted to be less than $0.01 PMPM.
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BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR ER, HER2- METASTATIC
BREAST CANCER PATIENTS IN THE UNITED STATES
Xie J1, Diener M1, De G1, Wu EQ2, Namjoshi M3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Novartis
Oncology US, East Hanover, NJ, USA
OBJECTIVES: To estimate the budget impact of everolimus as first-line metastatic
therapy for post-menopausal women who failed letrozole or anastrozole for treat-
ment of estrogen receptor positive (ER), human epidermal growth factor recep-
tor-2 negative (HER2-) metastatic breast cancer (MBC) from a third-party payer
perspective in the United States. METHODS: Pharmacy and medical budget im-
pacts were estimated over the first year of everolimus use in this specific indica-
tion. Published epidemiology data were used to estimate target population size.
Market share was assumed to be 100% exemestane before everolimus entry. Mar-
ket share for the combination therapy of everolimus and exemestane was pro-
jected to be 10%at the end of the first year after everolimus entry, andwas assumed
to increase linearly throughout the year. Components of pharmacy budget (whole-
sale acquisition cost of the therapies, daily dose, treatment duration, and copay-
ment) were obtained from unpublished data sources. Patients were assumed to be
on treatment until progression or death. Medical costs were estimated as the av-
erage costs for progression and non-progression weighted by the time in each
state. Progression and non-progression costs and time to progression for each
therapy were derived from published literature. All costs were reported in 2011 US
dollars. RESULTS: In a hypothetical health plan with 1 million members, the esti-
mated target population was 170. There were 17 patients expected to use the com-
bination therapy in the first year after everolimus entry, resulting in total incre-
mental plan costs of $0.025 per member per month (PMPM). While the pharmacy
budget was expected to increase by $0.038 PMPM, medical budget was expected to
decrease by $0.013 PMPM in the first year after everolimus entry. CONCLUSIONS:
Using everolimus for ER, HER2- MBC is expected to reduce medical budget due to
improved efficacy of combination therapy and increase pharmacy budget. The
total budget impact is relatively small.
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BUDGET IMPACT ANALYSIS OF MELANOMA TREATMENT IN MEXICO
Peniche-Otero G, Herrera-Rojas J, Ramírez-Ramírez MA, Nuño-Langre C, Baeza-Cruz G,
Bolaños-Cornejo D
Customized Premium Products S.A. de C.V., Mexico City, Mexico
OBJECTIVES: In Mexico, melanoma represents approximately 8% of the total num-
ber of cases of skin cancer, becoming the third most common skin cancer, behind
basal cell carcinoma and squamous cell carcinoma. There are few published stud-
ies describing the cost of care for patients withmelanoma inMexico. The objective
of this study is to estimate the budgetary impact on the total cost of 1 year of
treatment of melanoma in Mexico, regarding the perspective of the Social Security
Mexican Institute (IMSS) the most important health institution, serving more than
55 million people in Mexico. METHODS: In order to obtain the prescriptive habits
for the treatment of melanoma and the direct costs (including chemotherapy, ra-
diation therapy, surgery, assessment of the patient, laboratory and diagnostic
studies), we conducted 10 semi-structured face to face interviews with oncology
specialists from IMSS. Epidemiological indicators like incidence, prevalence and
mortality were obtained from a systematic review of national and international
literature. We consider beneficiaries of the IMSS as the target population of this
study. The distribution for the small sample was obtained using a non-parametric
bootstrap approach. As result, we get patients with melanoma who sought care
and which were correctly diagnosed in stages 3 and 4 of the disease, that is, those
who are candidates to receive chemotherapy. Finally, results were analyzed and
validated by experts. RESULTS: The number of patients with a diagnosis of mela-
noma in IMSS over the 1-year time horizon was 274. The estimated direct cost in
2011 USD, associated to melanoma treatment for 1-year was USD$16,661. In base
case analysis, the 1-year net budget impact was USD$4.5million (IC-95%: $4.1 - $4.9
million dollars). CONCLUSIONS: The budgetary impact of the treatment of mela-
noma in IMSS represents 0.16% of total budget expenditure in 2010 ($ 2,900.56
million dollars).
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DEVELOPING BUDGET IMPACT MODEL FOR RARE DISEASES: CASE IN POINT
CUTANEOUS T-CELL LYMPHOMA
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Develop budget impact model to forecast total cost of treatment for
cutaneous T-cell lymphoma (CTCL) for US public and private payer.METHODS:The
clinical efficacy and safety data were obtained from the published pivotal study
results. Costs of adverse events were estimated based on claims database analysis,
AHRQ’s HCUP and CMS Medicare 2009 databases. Drug cost was estimated based
on 2011 AWP price. Epidemiology data were obtained from NCI-SEER and CDC
databases. A budget impact model was implemented over a period of five years,
based on a stable population and on different penetration and substitution rates of
newly approved therapy. Model was developed in excel based format. Blinded
Model design and outputs were tested with payers and KOLs. RESULTS: For rare
cancers such as CTCL, the budget impact of treatment with targeted cancer ther-
apies is in the range of $460,000-$530,000 per 1 million covered lives. The per
patient per member (PPPM) budget impact of this treatment is 46-53 cents. US
payers rated PPPM output as the one of the most important relevant outputs of
model. CONCLUSIONS: This budget impact model shows that new treatments for
rare forms of cancer are likely to have minimal budget impact on payers. PPPM
based outputs are more relevant to payers, than per patient treatment costs. How-
ever, an emerging concern is the total budget impact of all therapies indicated for
ultra-orphan disorders, which might be an important consideration for future
models.
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ECONOMIC EVALUATION OF AZACITIDINE FOR THE TREATMENT OF
MYELODYSPLASTIC SYNDROMES (MDS) IN THE BRAZILIAN PUBLIC HEALTH
CARE SYSTEM (SUS)
Paladini L1, Pepe C2, Clark OAC1, Tencer T3, Khan Z3
1Evidencias, Campinas, SP, Brazil, 2MedInsight, São Paulo, SP, Brazil, 3Celgene Corporation,
Summit, NJ, USA
OBJECTIVES: MDS is an incurable and rare hematological disease that affects the
production of blood cells. Two hypomethylating agents for the treatment of MDS
are available in Brazil: azacitidine (AZA) and decitabine (DEC). Our aim was to
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